Biotechnology
3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development
HONG KONG, Aug. 26, 2021 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2021 interim results. 3SBio maintained strong performance in core businesses, with core products occupying a leading market share. Meanwhile, the Company continuously increased ...
2021-08-26 22:09
5336
Tigermed Reports 2021 Interim Results with Strong Financial Growth
HANGZHOU, China, Aug. 25, 2021 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (stock code: 300347.SZ / 3347.HK), a leading provider of innovative clinical research solutions for biopharmaceutical and medical device industry, reports its interim results for the six months endedJune 30, 202...
2021-08-25 20:49
5898
ExoCoBio to Build the World's First Clinical Grade Exosome GMP Manufacturing Facility
* $20 million investment for a new Mfg & R&D facility * Strategic platform for partnering & CDMO business SEOUL, South Korea, Aug. 25, 2021 /PRNewswire/ -- ExoCoBio Inc., the 4th largest exosome player in the world, announced the initiation of its "Project EGMP", starting with the constructio...
2021-08-25 19:44
1332
GenScript Biotech Reports First Half 2021 Results
* In the first half of 2021, the Group reported a revenue of approximately USD 229.6 million, a 38.0% YoY increase, and a gross profit of USD 138.6 million , achieving a 28.1% YoY growth. All four of the Group's business segments demonstrated steady growth. * Building on early strategic invest...
2021-08-24 21:38
6051
Kintor Pharma to Report 2021 Interim Financial Results and Host Conference Call on August 30, 2021
SUZHOU, China, Aug. 24, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today the company will review the interim results and business highlights on...
2021-08-24 17:04
2027
Hepagene Therapeutics, Inc. Announces Positive Results from Phase I Trial of HPG1860
SHANGHAI, Aug. 23, 2021 /PRNewswire/ -- Hepagene Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on novel therapies for patients with liver diseases, today announced positive results from its Phase I study of HPG1860 conducted inthe United States. HPG1860 is a non-bile aci...
2021-08-23 22:00
1250
PharmAbcine to Participate in H.C. Wainright 23rd Annual Global Investment Conference
DAEJEON, South Korea, Aug. 23, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participate in H.C. Wainright 23rd Annual Global Investment Confere...
2021-08-23 20:00
1226
Roche and KeChow Reach a Cooperation Agreement
SHANGHAI, Aug. 20, 2021 /PRNewswire/ -- On August 2, 2021, Shanghai Roche Pharmaceuticals Co., Ltd. (hereinafter referred to as "Roche Pharma China" or "Roche") and Shanghai KeChow Pharma, Inc. (hereinafter referred to as "KeChow Pharma" or "KeChow") entered into a cooperation agreement to improv...
2021-08-20 23:00
2768
Neurophth Expands Its Global Gene Therapy Leadership Team with the Appointment of Dr. Zhengbin Li as Head of Commercial
WUHAN, China and SAN DIEGO, Aug. 19, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integrated genomic medicines company committed to the development of AAV-delivered gene therapies for the treatment of ocular diseases, today announced the recent appointment of Dr. Zhengbin (Luke) Li ...
2021-08-19 22:00
1497
Daewoong Pharmaceutical and Hanall Biopharma Invest $1M USD in Alloplex Biotherapeutics
SEOUL, South Korea, Aug. 19, 2021 /PRNewswire/ -- Daewoong Pharmaceutical and
Hanall Biopharma ofSouth Korea are expanding their global open collaboration
initiative by investing in Alloplex Biotherapeutics, an emergingBoston-based
biotechnology company.
2021-08-19 21:00
1664
PharmAbcine Announces Submission of PCT for an Anti-ANG2 Antibody for the Treatment of Ocular Diseases
DAEJEON, South Korea, Aug. 19, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, today announced it submitted a Patent Cooperation Treaty (PCT), an international patent application, for ...
2021-08-19 20:00
1091
MicroConstants to Join BioAgilytix Family
Highly complementary transaction strengthens BioAgilytix's ability to support bioanalytical services across all major therapeutics in development; adds LC/MS/MS capabilities; and expands team of seasoned scientists DURHAM, N.C., Aug. 18, 2021 /PRNewswire/ -- BioAgilytix Labs, LLC (BioAgilytix),...
2021-08-19 02:30
1488
Henlius reports half-year (H1) 2021 results, outlines remarkable growth in commercialization and needs-driven innovation
SHANGHAI, Aug. 18, 2021 /PRNewswire/ -- Henlius (2696.HK) announced Half-Year (H1) results endedJune 30th, 2021, sharing the company's recent noteworthy progress and achievements. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innov...
2021-08-18 21:35
3687
PharmAbcine to Participate in Biotechgate Digital Partnering
DAEJEON, South Korea, Aug. 17, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participate in Biotechgate Digital Partnering taking place virtuall...
2021-08-17 20:00
1099
First Edition of World Conference on Early Detection of Cancer Set to Start in November in Hainan, China
GUANGZHOU and HAIKOU, China, Aug. 16, 2021 /PRNewswire/ -- Early detection and diagnosis of cancer is an essential enabler of curative treatment and an effective solution to boost the survival rates of cancer patients worldwide. In an effort to lead the way in innovative research and strategies f...
2021-08-16 22:13
1523
Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors
SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Aug. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...
2021-08-16 20:00
2275
Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19
TAIPEI and SAN DIEGO, Aug. 16, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focused on human efficacy and innovation of first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that its novel oral drug, Silmita...
2021-08-16 15:29
1404
GeneQuantum announces a key leadership appointment
SUZHOU, China, Aug. 15, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry leading biopharmacetucial company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announced a key appointment to further strengt...
2021-08-16 10:00
1210
InxMed's IN10018 Receives U.S. FDA Fast Track Designation for the Treatment of Platinum-resistant Ovarian Cancer
NANJING, China, Aug. 15, 2021 /PRNewswire/ -- InxMed (Nanjing) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today the U.S. Food and Drug Administration (FDA) has granted Fas...
2021-08-16 09:31
1334
Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ASEAN Countries and India
SHANGHAI, Aug. 15, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today the entering of an amendment to the exclusive license agreement with its partner Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), to expand the ...
2021-08-16 08:00
7378
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 317 media titles]
2024-05-03 06:59
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 295 media titles]
2024-04-30 10:11
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 287 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 262 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 253 media titles]
2024-04-30 15:13Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
11120
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
2024-04-30 10:11
7534
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
7148
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
6722
